Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer
Phase PHASE2
Enrollment 58
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase II study is a clinical study to explore the efficacy and safety of SI-B003 monotherapy and BL-B01D1+SI-B003 combination therapy in patients with unresectable locally advanced or recurrent metastatic HER-2 negative breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BL-B01D1 — BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.
  • Drug: SI-B003 — SI-B003 was administered by intravenous infusion on D1 in a 3-week cycle.

Primary Outcomes

  • Objective response rate (ORR) (Up to approximately 24 months)
  • Recommended Phase II Dose (RP2D) (Up to approximately 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-12-12
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 58 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Principal Investigators:
  • Jiong Wu, PHD (PRINCIPAL_INVESTIGATOR) - Fudan University
  • Jian Zhang, PHD (PRINCIPAL_INVESTIGATOR) - Fudan University
Contact Information
Study Contact:
Sa Xiao, PHD
+8615013238943
xiaosa@baili-pharm.com
Jiong Wu
Fudan University Shanghai Cancer Center
Jian Zhang
Fudan University Shanghai Cancer Center
Interventions
  • Drug: BL-B01D1 — BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.
  • Drug: SI-B003 — SI-B003 was administered by intravenous infusion on D1 in a 3-week cycle.
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality China
Eligibility Criteria
Inclusion Criteria: 1. Voluntarily sign the informed consent and follow the requirements of the protocol. 2. Age: ≥18 years old and ≤75 years old. 3. Expected survival time ≥3 months. 4. ECOG 0 or 1. 5. Pathologically and/or cytologically confirmed patients who have failed standard treatment, or have no access to standard treatment Patients with unresectable, locally advanced or recurrent, metastatic HER2-negative breast cancer after posterior line. 6. Agree to provide archived tumor tissue specimens (unstained sections (anti-slip)) from primary or metastatic sites within 2 years. 10 to 12 surgical specimens (4-5 μm thick) or fresh tissue samples if the subject is unable to provide them for 2 years tumor tissue samples from within, can be communicated with the sponsor if other inclusion criteria are met, enrollment was permitted after investigator assessment. 7. Must have at least one measurable lesion according to RECIST v1.1 definition; So let's say that we've done this before radiotherapy-treated lesions were included only if there was definite disease progression in the lesion after radiotherapy measurable lesions were entered. 8. Blood transfusions, the use of any cell growth factors, and/or blood transfusions were not allowed within 14 days before screening in the presence of a platelet drug, the organ function level must meet the following criteria: 1. Blood routine: hemoglobin (HGB) ≥ 90g/L; Absolute neutrophil count (NEUT) ≥ 1.5× 10 9 /L; Platelet count (PLT) ≥ 90× 10 9 /L; 2. Renal function: creatinine (Cr) ≤1.5 ULN, or creatinine clearance (Ccr) ≥50 mL/min (According to Cockcroft and Gault formula); 3. Liver function: total bilirubin (TBIL≤1.5 ULN), alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) was ≤2.5 ULN in all patients, and AST and ALT were ≤ in patients with liver metastasis 5.0 ULN; 4. Coagulation function: international normalized ratio (INR) ≤1.5 and activated partial thromboplastin time (APTT) ≤1.5ULN; 5. no severe cardiac dysfunction with left ventricular ejection fraction ≥50%; 6. proteinuria ≤2+ or ≤1000mg/24h. 9. Toxicity from previous antineoplastic therapy has returned to grade 1 or less as defined by NCI-CTCAE v5.0 (investigator review) concerns about asymptomatic laboratory abnormalities such as elevated ALP, hyperuricemia, hyperglycemia, etc., and investigators toxicity without safety risk was judged, such as alopecia, grade 2 peripheral neurotoxicity, or decreased hemoglobin but ≥90g/L except). 10. A pregnancy test should be performed within 7 days of starting treatment for premenopausal women who are likely to have children clear or urine pregnancy tests must be negative and must be non-lactating; All enrolled patients should be in the entire treatment week adequate barrier contraceptive measures were taken at the end of treatment and 6 months after the end of treatment. Exclusion Criteria: 1. ADC drugs that have received topoisomerase I inhibitors (camptothecins) as small molecule toxins. 2. Administration of chemotherapy or chemotherapy within 4 weeks or 5 half-lives, whichever is shorter, before the first dose physical therapy, immunotherapy, definitive radiotherapy, major surgery (investigator's definition), targeted therapy (including minor) molecular tyrosine kinase inhibitors) and other anti-tumor therapy; Oral fluorouracil drugs such as S-1, carboplatin ecitabine or palliative radiotherapy within 2 weeks before the first dose. 3. Use of immunomodulatory drugs within 14 days before the first use of the study drug: including but not limited to thymosin, interleukin-2, interferon, etc. 4. Systemic corticosteroids (\> 10mg/ day prednisone, or other corticosteroids in equivalent amounts); Inhaled or topical administration of hormones, or received physiology for adrenal insufficiency alternative doses of hormone therapy were excluded. 5. Patients with grade ≥3 irAE or grade ≥2 immune-related myocarditis who had received immunotherapy were excluded. 6. A history of severe cardiovascular and cerebrovascular diseases, including but not limited to: 1. severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias or grade III atria requiring clinical intervention Ventricular block; 2. prolonged QT interval at rest (QTc \> 450 msec in men or QTc \> 470 msec in women); 3. myocardial infarction, unstable angina, cardiac angioplasty, or within 6 months before the first dose Stent implantation, coronary artery/peripheral artery bypass grafting, New York Heart Association Defined class III or IV congestive heart failure, cerebrovascular accident, or transient ischemic attack. 7. Active autoimmune diseases and inflammatory diseases, such as systemic lupus erythematosus, silver requiring systemic treatment dandruptitis, rheumatoid arthritis, inflammatory bowel disease and hashimoto's thyroiditis, except type I diabetes, hypothyroidism that can be controlled only by replacement therapy, skin diseases that do not require systemic treatment (e.g., vitiligo, silver) Dandruff). 8. Other malignancies that progressed or required treatment within 3 years before the first dose, such as the following external: radical basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or radical carcinoma in situ. 9. History or current history of (noninfectious) interstitial lung disease (ILD)/pulmonary inflammation requiring steroid therapy patients with ILD/ pulmonary inflammation, or suspected ILD/ pulmonary inflammation that cannot be excluded by imaging at the time of screening. 10. Prior to starting the study treatment, there are: 1. Poorly controlled diabetes (fasting blood glucose ≥ 13.3 mmol/L) 2. Poorly controlled hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg) 3. History of hypertensive crisis or hypertensive encephalopathy. 11. Unstable deep vein thrombosis, arterial thrombosis, and pulmonary embolism requiring medical intervention within 6 months before screening thrombotic events such as plug; Infusion-related thrombosis was excluded. 12. Patients with central nervous system (CNS) metastases and/or carcinomatous meningitis (meningeal metastases). Patients who had received treatment for brain metastases (radiotherapy or surgery; Patients with stable brain metastases who had stopped radiotherapy or surgery 28 days before the first dose were eligible. Patients with cancerous meningitis (meningeal metastasis) were excluded even if they were treated and judged to be stable. Stability is defined as meeting the following four criteria: 1. seizure-free status for \> 12 weeks with or without antiepileptic medication; 2. no need for corticosteroids; 3. stable on two consecutive MRI scans (at least 4 weeks apart); 4. stable and asymptomatic for more than one month after treatment. 13. Patients with pleural effusion, pericardial effusion or ascites with clinical symptoms or requiring repeated drainage. 14. Allergic history to recombinant humanized antibody or human-mouse chimeric antibody or any excipients of BL-B01D1 sensitive patients. 15. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT). 16. Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, or active hepatitis C virus infection (HCV antibody positive and HCV-RNA \> lower detection limit). 17. Positive hepatitis B surface antigen (HBsAg) and HBV DNA\> 500IU/ml or 2000 copies /ml patients with HBV infection should receive antiviral treatment according to local treatment guidelines and be willing to participate in the study all patients received antiviral therapy during the whole period. 18. Active infection requiring systemic treatment, such as severe pneumonia, bacteremia, sepsis, etc. 19. Had participated in another clinical trial within 4 weeks before the first dose (calculated from the time of last dose). 20. Persons with a history of psychotropic drug abuse
Conditions Depression Mild, Depression Moderate
Phase NA
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this single-center, single-blind, randomized, controlled, parallel group, interventional trial is to evaluate antidepressant efficacy of yoga monotherapy of 12-weeks duration in 180 adults meeting diagnostic criteria for mild-to-moderate major depression at the Zuckerberg San Francisco General Hospital. Researchers will compare the yoga interventions to an education control intervention on holistic healthcare.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Yoga practice — 90-minute group yoga classes twice weekly for 12 weeks.
  • Behavioral: Education — 90-minute group education classes twice weekly for 12 weeks to learn holistic healthcare modules.

Primary Outcomes

  • Change in Beck Depression Inventory-II score (Baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks and 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-25
Completion: 2026-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Francisco
Principal Investigators:
  • Sudha Prathikanti, MD (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
Contact Information
Study Contact:
Sudha Prathikanti, MD
415-516-3867
sudha.prathikanti@ucsf.edu
Sudha Prathikanti, MD
415-516-3867
sudha.prathikanti@gmail.com
Zuckerberg San Francisco General Hospital
Sudha Prathikanti, MD
Zuckerberg San Francisco General Hospital
Interventions
  • Behavioral: Yoga practice — 90-minute group yoga classes twice weekly for 12 weeks.
  • Behavioral: Education — 90-minute group education classes twice weekly for 12 weeks to learn holistic healthcare modules.
Study Locations (1 sites)
Zuckerberg San Francisco General Hospital, San Francisco, California 94110 United States
Eligibility Criteria
Inclusion criteria: * 18 years of age or older * Able to give voluntary, informed consent * English-speaking * Diagnosis of clinical depression Exclusion criteria: * Current use of antidepressant medication * Current engagement in psychotherapy * Current pregnancy * Significant medical issues interfering with yoga practice
Conditions Depression, Depression Moderate
Phase NA
Enrollment 220
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Considering that one out of five people may experience depression during the course of their life, and that compliance to anti-depression medication is often not optimal. Psycho-educational interventions are recommended in international clinical practice guidelines for the management of depression. They are the first step in the treatment protocol. Psychoeducation in the treatment of depressive episodes has been shown to be an effective intervention because it reduces depressive symptoms, the risk of relapse or recurrence and improves adherence to treatment. In France, there are only one approved psycho-education programme, but it concerns a population of patients under psychiatric care. No psycho-education programme has yet been carried out or evaluated in France on depressed patients followed up in primary care by their General Practitioner. Recent changes in our healthcare practices, which have required adaptation to the pandemic context, have led to the development of the use of telemedicine. This study aims to evaluate a new and 100% remote educational program adapted to patients ongoing moderate depression and focused on medication adherence, economic gain and patients and professional satisfaction.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: psychoeducative program — The tele-education program consists of 5 sessions and is designed to adapt to changes in depressive symptoms over time. Each session will last an average of 60 minutes. They will be scheduled every week for 5 weeks. The first session is devoted to educational diagnosis, with identification of the patient's needs and any barriers to treatment. The second session will focus on personalised hygienic and dietary measures. A third session will focus on identifying the symptoms of depression, with a particular focus on suicidal ideation and the causes of depression. The role of family and friends will also be discussed. A fourth session will be devoted to providing clear information on antidepressants, with particular attention to the duration of treatment. The aim of the final session is to identify what has been learned and to clarify any questions before drawing up a joint summary of the work done, which will be sent to the patient's GP with his or her consent.

Primary Outcomes

  • medication adherence (6 months post inclusion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-25
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 220 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Toulouse
Principal Investigators:
  • Marion LASSERRE (PRINCIPAL_INVESTIGATOR) - University Hospital, Toulouse
Contact Information
Study Contact:
Marion LASSERRE, NURSE
05 61 77 60 41
LASSERRE.M@CHU-TOULOUSE.FR
MARION LASSERRE, NURSE
05 61 77 60 41
lasserre.ma@chu-toulouse.fr
Chu Toulouse
SOPHIE PREBOIS, MD
prebois.s@chu-toulouse.fr
Chu Toulouse
Interventions
  • Other: psychoeducative program — The tele-education program consists of 5 sessions and is designed to adapt to changes in depressive symptoms over time. Each session will last an average of 60 minutes. They will be scheduled every week for 5 weeks. The first session is devoted to educational diagnosis, with identification of the patient's needs and any barriers to treatment. The second session will focus on personalised hygienic and dietary measures. A third session will focus on identifying the symptoms of depression, with a particular focus on suicidal ideation and the causes of depression. The role of family and friends will also be discussed. A fourth session will be devoted to providing clear information on antidepressants, with particular attention to the duration of treatment. The aim of the final session is to identify what has been learned and to clarify any questions before drawing up a joint summary of the work done, which will be sent to the patient's GP with his or her consent.
Study Locations (1 sites)
Chu Toulouse, Toulouse, Occitanie 31000 France
Eligibility Criteria
Inclusion Criteria: * Presenting a depressive episode of moderate intensity according to the Diagnostic and Statistical Manual (DSM)-V * With a prescription for an antidepressant started less than 2 months before inclusion in the trial. * Whose state of health is compatible with follow-up by their GP (possibility of occasional advice from a psychiatrist). * Have Internet access at home (computer) and are able to use the digital platform. Exclusion Criteria: * Patients who are unable to complete self-questionnaires (language barrier, etc.) * Who have already undergone a psycho-education or therapeutic patient education programme regarding depression. * Whose state of health requires follow-up by a psychiatrist
Conditions Depression, Anxiety, Fear, Depression, A...
Phase PHASE4
Enrollment 165
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This mechanistic study uses an anti anxiety drug and brain imaging to study the threat processing system and associated brain circuits in people with depression, anxiety disorders and comorbid depression and anxiety disorders. In a double blind, placebo controlled crossover design, up to 65 individuals will be recruited who will have a diagnosis of major depressive disorder (MDD) and at least one anxiety disorder (AD) (AD-MDD group), up to 65 participants will have a diagnosis of MDD and no diagnosis of an AD and up to 65 participants will have no diagnosis of MDD and a diagnosis of at least one AD will be enrolled to participate in an two session study to obtain 150 completers (50 per group). All participants will receive a single dose of Lorazepam and placebo (order randomized) taken orally. After the \~2.5 hr screening session, participants will complete two identical \~5 hr experimental sessions, each of which include a 30 min eyeblink startle session and a 1.5 hr functional magnetic resonance imaging (MRI) brain scan session. The total time involved in the study is approximately 10.5 hours. The main questions the study seeks to answer are: * are people with comorbid depression and anxiety different than those with depression alone in terms of their eyeblink startle response to threat? * are people with comorbid depression and anxiety different than those with depression alone in terms of their brain activation in response to threat? * are people with comorbid depression and anxiety different than those with depression alone in terms of their responses to anxiety drugs?

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Lorazepam — 1mg of Lorazepam will be prepared by pharmacy (Barnes, Tulsa) in capsule form
  • Other: Placebo — placebo will be prepared by pharmacy (Barnes, Tulsa) in capsule form

Primary Outcomes

  • Eyeblink startle magnitude under threat in AD-MDD compared to MDD. (1-2 hours after single session placebo administration, an average of 1-5 weeks after enrollment (placebo could be session 1 or session 2))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2023-11-08
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 165 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Laureate Institute for Brain Research, Inc.
Collaborators: National Institute of Mental Health (NIMH), California Institute of Technology
Principal Investigators:
  • Maria Ironside, DPhil (PRINCIPAL_INVESTIGATOR) - Laureate Institute for Brain Research
Contact Information
Study Contact:
Maria Ironside, DPhil
16174175065
mironside@laureateinstitute.org
Maria A Ironside, DPhil
617-417-5065
mironside@laureateinstitute.org
Laureate Institute for Brain Research
Maria Ironside, DPhil
Laureate Institute for Brain Research
Interventions
  • Drug: Lorazepam — 1mg of Lorazepam will be prepared by pharmacy (Barnes, Tulsa) in capsule form
  • Other: Placebo — placebo will be prepared by pharmacy (Barnes, Tulsa) in capsule form
Study Locations (1 sites)
Laureate Institute for Brain Research, Tulsa, Oklahoma 74136 United States
Eligibility Criteria
An individual must meet the following criteria to be considered eligible to participate in the study: Inclusion Criteria: All subjects: * Female or male sex assigned at birth; * Age 18-65; * Normal or corrected to normal vision/hearing, as protocol elements may not be valid otherwise; * Fluent English speaker, capable of providing written informed consent MDD and AD-MDD subjects: * Current major depressive episode assessed by clinician with guidance from the MINI; * Minimum score of 55 on PROMIS Depression scale AD and AD-MDD subjects: * Current anxiety disorder (generalized anxiety disorder, panic disorder, agoraphobia and social phobia) assessed by clinician with guidance from the MINI; * Minimum score of 55 on PROMIS Anxiety Scale Exclusion Criteria: All subjects: * Has uncontrolled, clinically significant neurologic (including seizure disorders): cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, endocrine disease, or psychiatric disorder, or other abnormality, which may impact the ability of the subject to participate or potentially confound the study results; * Reported body mass index (BMI) \> 40; * History of moderate or severe traumatic brain injury, as assessed by a TBI questionnaire; * History of eating disorder or obsessive-compulsive disorder, schizophrenia, schizo-affective disorder, bipolar disorder or any sign of psychosis; * Current post-traumatic stress disorder (PTSD) diagnosis (although history of trauma is allowed); * Current use of medications with major effects on brain function or the fMRI hemodynamic response (e.g., methylphenidate, acetazolamide, excessive caffeine intake \> 1000 mg/day) following an initial list compiled by LIBR but also assessed on a case-by-case basis. Individuals who are currently on medication (antidepressants such as SSRIs, TCAs, SNRIs, and Bupropion) and who have not undergone dose or medication changes over the past 6 weeks will be allowed to participate; * Current benzodiazepine or opiate use; * Moderate to severe current substance use disorder, defined as 5 or more symptoms of the criteria for Substance Use Disorder according to DSM 5; * Drug or alcohol intoxication (based on positive UTOX or breathalyzer test at screening or study session) or reported alcohol/drug withdrawal, last cannabis use must be \>48 hours prior to study session; * Has a risk of suicide according to the Investigator's clinical judgement or per Columbia-Suicide Severity Rating Scale (C-SSRS) or equivalent PhenX instrument, the subject scores "yes" on items 4 or 5 in the Suicidal Ideation section with referent to a 30-day period prior to Screening/Baseline or the subject has had one or more suicidal attempts with reference to a 2-year period prior to Screening; * MRI contraindications; * Is pregnant or lactating or intending to become pregnant before, during, or within 12 weeks after participating in this study; or intending to donate ova during this time-period; * Any subject judged by the Investigator to be inappropriate for the study. MDD subjects: * Current (assessed by clinician with guidance from the MINI) anxiety disorder; * Score of \> 60 on PROMIS Anxiety Scale AD subjects: * Current or past recurrent major depressive episodes assessed by clinician with guidance from the MINI; * Score of \> 60 on PROMIS Depression scale
Conditions Breast Cancer
Phase PHASE2
Enrollment 144
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multi-center, randomized, prospective phase II clinical trial aimed at exploring and evaluating the efficacy of dalpiciclib combined with AI in neoadjuvant treatment for ER strong positive(ER≥50%),HER2-negative, Ki-67≤20%,T1-3N1M0 postmenopausal breast cancer. The primary objectives are to demonstrate non-inferiority in efficacy compared to chemotherapy and to assess its superior safety profile.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Dalpiciclib — Dalpiciclib: Take 125 mg once daily for 3 weeks, then stop for 1 week. Each cycle is completed in 4 weeks. It is recommended to take the medication approximately at the same time each day, with warm water, preferably on an empty stomach. Fasting for at least 1 hour before and after medication is advised.
  • Drug: Aromatase inhibitor — AI: Take according to the instructions provided.
  • Drug: Docetaxel injection — Administered as a 75 mg/m2 intravenous infusion over approximately 30 minutes. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
  • Drug: Epirubicin Hydrochloride Injection — Administered as a 75 mg/m2 intravenous infusion. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
  • Drug: Cyclophosphamide injection — Administered as a 500 mg/m2 intravenous infusion. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.

Primary Outcomes

  • Percentage of Participants With Complete Radiologic Response or Partial Radiological Response: Radiological Response (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-09-30
Completion: 2028-12-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 144 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hebei Medical University Fourth Hospital
Contact Information
Study Contact:
lina zhang
15830981676
linazh_001@163.com
Cuizhi Geng, M.D.
0311-6669 6310
gengcuizhi@hotmail.com
The Fourth Hospital of Hebei Medical University
Interventions
  • Drug: Dalpiciclib — Dalpiciclib: Take 125 mg once daily for 3 weeks, then stop for 1 week. Each cycle is completed in 4 weeks. It is recommended to take the medication approximately at the same time each day, with warm water, preferably on an empty stomach. Fasting for at least 1 hour before and after medication is advised.
  • Drug: Aromatase inhibitor — AI: Take according to the instructions provided.
  • Drug: Docetaxel injection — Administered as a 75 mg/m2 intravenous infusion over approximately 30 minutes. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
  • Drug: Epirubicin Hydrochloride Injection — Administered as a 75 mg/m2 intravenous infusion. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
  • Drug: Cyclophosphamide injection — Administered as a 500 mg/m2 intravenous infusion. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
Study Locations (1 sites)
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011 China
Eligibility Criteria
Inclusion Criteria: 1. Sign the informed consent form to participate in the clinical research. 2. Confirmed postmenopausal females diagnosed with invasive breast cancer. 3. Clinical stage T1-3N1M0. 4. Pathological examination confirmed: Strong positive for ER, negative for HER2. HER2 negative: Immunohistochemistry (IHC) suggests HER2 (-, +) or (++) but in situ hybridization (ISH) indicates negative. Strong positive for ER: ER immunohistochemistry test shows 50% or more tumor cells positive. 5. No prior breast cancer-related treatment. 6. No concurrent cardiac diseases, baseline left ventricular ejection fraction (LVEF) ≥ 50%, no significant cardiac diseases (≤ NYHA class I). 7. ECOG score of 0-1, meeting the indications and basic requirements for chemotherapy without major organ dysfunction. 8. Within 1 week prior to enrollment, routine blood tests are essentially normal: Absolute neutrophil count (NEUT#) ≥ 1.5×10\^9 /L; White blood cell count (WBC) ≥ 3.0×10\^9 /L; Platelets ≥ 90×10\^9 /L; Hemoglobin ≥ 90 g/L. 9. Within 1 week prior to enrollment, liver and kidney function tests are essentially normal: Total bilirubin (TBIL) ≤ 1.5× upper limit of normal (ULN); Alanine aminotransferase and aspartate aminotransferase (ALT/AST) ≤ 2× ULN; Serum creatinine ≤ 1.5× ULN or creatinine clearance rate (Ccr) ≥ 60 ml/min. 10. For women of childbearing age, negative serum or urine pregnancy test results before participation; premenopausal women during the study period should use medically acceptable methods of contraception. 11. Exhibits good compliance. Exclusion Criteria: 1. Pregnant or lactating women, and women of childbearing age who have a positive pregnancy test at baseline and do not agree to use effective contraception during the study. 2. Patients with a known history of severe allergic reactions to any investigational drug components (NCI-CTCAE Grade \> 3) or with any clearly documented drug allergy. 3. Patients with bilateral breast cancer or inflammatory breast cancer. 4. Patients with metastatic (stage IV) breast cancer at initial diagnosis. 5. Patients with a history of congestive heart failure, unstable angina, arrhythmias, or myocardial infarction. 6. Current diagnosis of acute lung conditions, interstitial lung disease, pulmonary fibrosis, acute pulmonary disease, etc. 7. Current diagnosis of severe liver-related diseases such as acute hepatitis, fulminant hepatitis, coagulation factor synthesis disorders. If HBV surface antigen or HBV core antibody are positive, the peripheral blood HBV DNA titer should be \< 1×10\^3 IU/ml for eligibility. 8. Any other serious medical condition or comorbidity that may interfere with participation in the study or may significantly affect the safety of the subject (e.g., active or uncontrolled infections, active or requiring antiviral therapy for liver and bile diseases). 9. Other invasive malignancies (including second primary breast cancer) that may interfere with the evaluation of study endpoints and compliance with the protocol. 10. Patients with a history of prior treatment with chemotherapy, endocrine therapy, or anti-HER2 biologic therapy for breast cancer (excluding diagnostic biopsy for primary breast cancer). 11. Patients who have undergone major surgery within 4 weeks prior or have significant unresolved medical conditions. 12. Patients with non-measurable tumors during treatment. 13. Any other condition that the investigator deems unsuitable for the participation of the subject in the study.
Conditions Breast Cancer, Breast Cancer Stage II, B...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This purpose of this study is to examine skin reactions (called radiation dermatitis) that occur during pencil beam scanning (PBS) proton therapy. The researchers will test a unique technique called "Spot Delete" to see if it can reduce skin reactions for breast patients treated with PBS. They will also use a special computer model to study how the energy of the proton beam (linear energy transfer) is related to these skin reactions. The study involves creating a treatment plan based on a CT scan, which helps guide the proton beam in the body. The clinical team uses this CT scan to find the best placement for the protons. The "Spot Delete" method prevents protons from stopping in the skin, which is thought to cause skin redness.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Radiation: Pencil Beam Scanning Proton Therapy — Part of the normal proton therapy process is to have a CT scan (called a CT simulation) performed that is used to create a proton treatment plan. A proton treatment plan is a computer model of the proton beam that is used to calculate where the protons will go inside the body. During the treatment planning process, the clinical team works to find the best possible placement of the protons. This study uses a process called "Spot Delete" to keep protons from stopping in the skin, which is believed to be related to skin reddening. Spot Delete is a software application that was developed at the Thompson Proton Center and is used in the treatment planning process.

Primary Outcomes

  • Reduction in Radiation Dermatitis (weekly assessments over 10 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-07-07
Completion: 2030-07-07
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Covenant Health Cancer Center
Principal Investigators:
  • Samantha Hedrick, PhD (PRINCIPAL_INVESTIGATOR) - Director of Medical Physics
Contact Information
Study Contact:
Samantha Hedrick
865-862-1600
shedrick@covhlth.com
Chester Ramsey, PhD
865-331-3161
cramsey@covhlth.com
Casey Mastio-Partridge, BS, MLS
865-331-8216
cmastio@covhlth.com
Thompson Proton Center
Interventions
  • Radiation: Pencil Beam Scanning Proton Therapy — Part of the normal proton therapy process is to have a CT scan (called a CT simulation) performed that is used to create a proton treatment plan. A proton treatment plan is a computer model of the proton beam that is used to calculate where the protons will go inside the body. During the treatment planning process, the clinical team works to find the best possible placement of the protons. This study uses a process called "Spot Delete" to keep protons from stopping in the skin, which is believed to be related to skin reddening. Spot Delete is a software application that was developed at the Thompson Proton Center and is used in the treatment planning process.
Study Locations (1 sites)
Thompson Proton Center, Knoxville, Tennessee 37909 United States
Eligibility Criteria
Inclusion Criteria: * The patient must consent to be in the study and must have signed an approved consent form conforming to federal and institutional guidelines. * Patients must be equal to or greater than 18 years old. * The patient must have stage 0, I, II, or III breast cancer * On histological examination, the tumor must be ductal carcinoma in-situ (DCIS) or invasive adenocarcinoma of the breast * Surgical treatment of the breast must have been lumpectomy or mastectomy * Patients must have an estrogen receptor (ER) analysis performed on the primary tumor * Progesterone (PgR) analysis is desired but not mandatory * No serious health conditions as determined by physician that would impact ability to complete treatment or impact skin in the area of treatment Exclusion Criteria: * Stage IV breast cancer * Non-epithelial breast malignancies such as sarcoma or lymphoma * Paget's disease of the nipple * Prior breast or thoracic radiation therapy (RT) for any condition. * Collagen vascular disease, specifically dermatomyositis with a Creatine phosphokinase (CPK) level above normal or with an active skin rash, systemic lupus erythematosis, or scleroderma. * Pregnancy or lactation * Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements.
Conditions Asthma
Phase Not Applicable
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to examine the mechanisms of asthma. The investigators are comparing the cells of individuals with and without asthma and looking at the roles various parts of the cell play in the production and secretion of mucus.

Design

Study type: Observational Observational model: Case Control Time perspective: Cross Sectional

Primary Outcomes

  • Quantitate mean gene expression of TSPAN8 in goblet cells from the airways of human asthma and health and report the mean for asthma and health (main outcome 1) and for both goblet cells and non-goblet cells in asthma. (Between 1-12 weeks)
  • Quantitate KRT8 in airway cells from human asthma vs health and report the mean level in the transitional secretory cell subset for both asthma and health. (Between 1-12 weeks)
  • Quantitate expression of miR-141/200 family members report mean expression for the transitional secretory cell population in human asthma vs health using methods similar to those in Outcomes 1 and 2. (Between 1-12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-07-01
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Francisco
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigators:
  • Nirav Bhakta, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
  • Prescott Woodruff, MD, MPH (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
Contact Information
Study Contact:
Christine P Nguyen, BS
628-233-1233
christine.nguyen@ucsf.edu
Christine Nguyen, BS
628-233-1233
christine.nguyen@ucsf.edu
University of California, San Francisco
Interventions
N/A
Study Locations (1 sites)
University of California, San Francisco, San Francisco, California 94143 United States
Eligibility Criteria
Inclusion Criteria: * Healthy Controls 1. Male and female subjects between the ages of 18 and 70 years 2. Ability to provide written informed consent and ability to comply with the requirements of the study 3. No hyperreactivity to methacholine (PC20 FEV1 Methacholine \>16 mg/mL) 4. No history of allergic rhinitis/seasonal allergies * Asthmatics 1. Male and female subjects between the ages of 18 and 70 years 2. Ability to provide written informed consent and ability to comply with the requirements of the study 3. History of asthma 4. No use of oral or inhaled corticosteroids for the treatment of asthma during the past 6 weeks 5. Hyperreactivity to methacholine (PC20 FEV1 Methacholine \< 8 mg/ml) Exclusion Criteria: The same exclusion criteria will apply to both Sub-studies. 1. Current smokers, defined by (a) \>5 cigarettes smoked in past 12 months, and (b) ≤ 8 weeks since last time smoking; or former smokers who have a total smoking history * 10 pack-years 2. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study 3. Subjects with a history of lung disease other than asthma 4. Subjects with a history of prior esophageal hernia surgery 5. Subjects with a history of a medical disease, which in the opinion of the Investigator may put the subject at extra risk from study-related procedures or because the disease may influence the results of the study 6. Current participation in an investigational drug trial Prohibited Medications and Treatments The following medications are prohibited during the study and must be discontinued prior to enrollment for the amount of time specified below. 1. Astemizole: 12 weeks 2. Steroids (oral, inhaled or nasal): 6 weeks 3. Nedocromil sodium, sodium cromoglycate: 4 weeks 4. Long-acting methylxantines: 2 days 5. Short-acting methylxantines: 12 hours 6. Montelukast: 7 days 7. Zafirlukast: 7 days 8. Salmeterol: 2 days 9. Omalizumab: 6 months Medications to be withheld prior to bronchoscopy: Aspirin or Non- steroidal anti-inflammatory agents (NSAIDs) for 2 days Medications to be withheld before each clinic visit: Short-acting bronchodilators (e.g. Albuterol) for 6 hours; Short-acting anti- cholinergics (e.g. Atrovent, Combivent) for 8 hours; and antihistamines (e.g. Benadryl, Claritin) for 3 days.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 150
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The time taken to obtain the results of germline mutations in BRCA1 and BRCA2 has become a major issue in adapting the therapeutic management of patients, particularly those with breast cancer. The time taken to obtain the results of BRCA1/2 tests in routine laboratories with a view to personalised treatment can range from a few weeks to a few months. The waiting time required to obtain results is likely to cause stress and anxiety in cancer patients. The investigators hypothesise that ultra-rapid testing can reduce anxiety about patients' genetic status and improve their mental well-being. The main objective of this project is to compare the results obtained with an ultra-fast kit developed by O.N.T with those obtained with the current gold standard, NGS sequencing.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Questionnaires — 3 questionnaires to allowed to assess satisfaction and acceptance of the nanopore ultrafast test by practitioners and anxiety of results by patients : * STAI-Y (State-Trait Anxiety Inventory) * Patient's Questionnaire * Practitioner's questionnaire
  • Other: Communication of the results of the BRCA1/2 ultra rapid test — Communication of the results of the BRCA1/2 ultra rapid test during a consultation 1 to 2 weeks after the test

Primary Outcomes

  • Compare the results obtained with an ultra-rapid kit BRCA1/2 with those obtained with the current gold standard, by checking the sensitivity, specificity and the rate of patients correctly classified for BRCA1 and 2 status (During 2 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-06-12
Completion: 2026-09-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Georges Francois Leclerc
Contact Information
Study Contact:
Manon REDA, Dr
03.80.73.75.00
mreda@cgfl.fr
Emilie REDERSTORFF, Project Manager
03 45 34 81 16
erederstorff@cgfl.fr
Manon REDA, Dr
03 80 73 75 00
mreda@cgfl.fr
Centre Georges-François Leclerc
Interventions
  • Other: Questionnaires — 3 questionnaires to allowed to assess satisfaction and acceptance of the nanopore ultrafast test by practitioners and anxiety of results by patients : * STAI-Y (State-Trait Anxiety Inventory) * Patient's Questionnaire * Practitioner's questionnaire
  • Other: Communication of the results of the BRCA1/2 ultra rapid test — Communication of the results of the BRCA1/2 ultra rapid test during a consultation 1 to 2 weeks after the test
Study Locations (2 sites)
Centre Georges-François Leclerc, Dijon, 21000 France
Institut Rafaël, Levallois-Perret, 92300 France
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Indication for oncogenetic consultation with a wide panel test including BRCA1/2 (gold standard) as part of the standard theranostic and diagnostic management of breast cancer. * The patient agrees to take part in the study, to follow all the study procedures and to complete the questionnaires sent during the consultation or by email. * Diagnosis of the disease ≤ 6 months * The patient must be affiliated to the social security system. Exclusion Criteria: * Concomitant disorder or condition likely to compromise understanding of study information or completion of questionnaires * Patients who do not have an email address and/or do not have internet access or tools to connect to the internet * Women who are pregnant, may become pregnant or are breast-feeding * Persons deprived of their liberty or under guardianship (including curatorship) * Inability to undergo trial monitoring for geographical, social or psychological reasons.
Conditions HER2-positive Breast Cancer, Advanced Br...
Phase NA
Enrollment 260
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to test whether four different supportive care programs can reduce fatigue in women with advanced or metastatic breast cancer who are receiving a medication called a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) alongwith endocrine therapy with or without a PI3K or AKT inhibitor.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Prolonged Overnight Fasting — Participants will undergo a 12-week program of prolonged overnight fasting (POF) during which they will abstain from consuming food or drink after 8pm, and wait 12 to 14 hours before resuming eating the next day. Participants will fast overnight for six nights each week, with one night off, and log their fasting start and stop times and timing of food intake daily via text messaging, or via study-provided app accessible by web browser or smart phone, or via paper journal returned by mail at the end of each month. Participants will also complete one weekly session with a health coach to review their fasting log and any barriers to and/or facilitators of meeting the POF goals. Sessions may be delivered in-person, by telephone, or by video call based on participant preference. Sessions will last 15 to 30 minutes each, for a total of 12 sessions. Participants will be provided with a notebook with information and support to encourage meeting the POF goals.
  • Behavioral: Moderate-Intensity Exercise — Participants will undergo a 12-week program consisting of three weekly sessions of moderate-to-vigorous aerobic and resistance exercises, under the supervision of a health coach. Sessions may be delivered either in-person or virtually via telehealth. Sessions will be tailored to the individual participant based on fitness level and symptoms at study entry, and limited to daylight hours as much as possible. Each session will last 30 to 50 minutes, as tolerated by the participant, for a total of 36 sessions. Participants will receive a Fitbit device to track their activity, and to provide heart rate monitoring during each session. Participants without access to wi-fi will be loaned cellular-enabled tablets to allow them to participate in telehealth sessions. Participants will also receive a notebook with information and support to encourage exercise.
  • Behavioral: General Health Education Sessions — Participants will receive a general health education resource manual at study entry, followed by six bi-weekly sessions with a health coach to review the information. Six topics, one topic for each session, will be selected based on topics of potential interest to a population living with advanced breast cancer, focusing on general nutrition, healthy lifestyle, and quality of life, with no discussion of prolonged overnight fasting or exercise. Each session, administered via telephone or video call, will last about 15 to 30 minutes, and have a specific topic and call script for the health coach to follow to minimize any intervention drift and/or contamination. Participants will receive a Fitbit activity monitoring device and additional study materials at the end of their participation in the study.

Primary Outcomes

  • Change in Cancer-Related Fatigue as Measured by EORTC QLQ-C30 Scores (Baseline, 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-09
Completion: 2029-09-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 260 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Miami
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Tracy E Crane, PhD, RDN (PRINCIPAL_INVESTIGATOR) - University of Miami
  • Carmen Calfa, MD (PRINCIPAL_INVESTIGATOR) - University of Miami
Contact Information
Study Contact:
Grey Freylersythe, BS
(305) 243-9832
g.freylersythe@med.miami.edu
Tracy E Crane, PhD, RDN
(305) 243-8255
tecrane@med.miami.edu
Dorothy Sears, PhD
(602) 496-3351
dorothy.sears@asu.edu
Arizona State University
Interventions
  • Behavioral: Prolonged Overnight Fasting — Participants will undergo a 12-week program of prolonged overnight fasting (POF) during which they will abstain from consuming food or drink after 8pm, and wait 12 to 14 hours before resuming eating the next day. Participants will fast overnight for six nights each week, with one night off, and log their fasting start and stop times and timing of food intake daily via text messaging, or via study-provided app accessible by web browser or smart phone, or via paper journal returned by mail at the end of each month. Participants will also complete one weekly session with a health coach to review their fasting log and any barriers to and/or facilitators of meeting the POF goals. Sessions may be delivered in-person, by telephone, or by video call based on participant preference. Sessions will last 15 to 30 minutes each, for a total of 12 sessions. Participants will be provided with a notebook with information and support to encourage meeting the POF goals.
  • Behavioral: Moderate-Intensity Exercise — Participants will undergo a 12-week program consisting of three weekly sessions of moderate-to-vigorous aerobic and resistance exercises, under the supervision of a health coach. Sessions may be delivered either in-person or virtually via telehealth. Sessions will be tailored to the individual participant based on fitness level and symptoms at study entry, and limited to daylight hours as much as possible. Each session will last 30 to 50 minutes, as tolerated by the participant, for a total of 36 sessions. Participants will receive a Fitbit device to track their activity, and to provide heart rate monitoring during each session. Participants without access to wi-fi will be loaned cellular-enabled tablets to allow them to participate in telehealth sessions. Participants will also receive a notebook with information and support to encourage exercise.
  • Behavioral: General Health Education Sessions — Participants will receive a general health education resource manual at study entry, followed by six bi-weekly sessions with a health coach to review the information. Six topics, one topic for each session, will be selected based on topics of potential interest to a population living with advanced breast cancer, focusing on general nutrition, healthy lifestyle, and quality of life, with no discussion of prolonged overnight fasting or exercise. Each session, administered via telephone or video call, will last about 15 to 30 minutes, and have a specific topic and call script for the health coach to follow to minimize any intervention drift and/or contamination. Participants will receive a Fitbit activity monitoring device and additional study materials at the end of their participation in the study.
Study Locations (3 sites)
Arizona State University, Phoenix, Arizona 85004 United States
University of Miami, Miami, Florida 33136 United States
Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States
Eligibility Criteria
Inclusion Criteria: 1. Women 2. Able to provide written informed consent 3. Able to speak, read, and understand English or Spanish 4. Postmenopausal (including concurrent use of ovarian suppression) 5. Diagnosis of ER+ and/or PR+, hormone estrogen receptor-2 (HER-2)- or HER-2+ metastatic or locally advanced unresectable breast cancer 6. Initiation of endocrine therapy in combination with a CDK4/6 inhibitor (e.g., palbociclib, ribociclib, or abemaciclib), with or without hormone estrogen receptor-2 (HER2)-directed therapy (e.g., trastuzumab ± pertuzumab), or in combination with both a CDK4/6 inhibitor and a Phosphoinositide 3-kinase (PI3K) or Protein kinase B (AKT) inhibitor, within the past 90 days. a) Participants who switch from one CDK4/6 inhibitor to another due to toxicity or insurance constraints remain eligible, provided enrollment occurs within 90 days of initiating the subsequent CDK4/6 inhibitor in the metastatic or locally advanced setting. 7. Having not consistently (not equal to or more than 50% of the time) engaged in more than 90 minutes of moderate or 45 minutes of vigorous physical activity per week over the past 3 months 8. Having not consistently engaged in resistance training 2 or more days per week over the past 3 months 9. Having not consistently (not equal to or more than 50% of the time) engaged in structured fasting (i.e., not regularly fasting for ≥12hr/night) for the past 3 months 10. Approval from a medical oncology provider to participate. Exclusion Criteria: 1. Unable to provide consent 2. Unable to read or understand English or Spanish 3. Dependent on supplemental oxygen 4. Unstable cardiac disease 5. Insulin-dependent diabetes 6. Unable to walk 2 blocks without assistance (excluding canes) 7. Regularly maintaining a shiftwork schedule, i.e. working evening shifts, night shifts, or rotating shifts in the last 3 months 8. History of a clinical eating disorder 9. Unstable bone metastases 10. More than 90 days since initiation of endocrine therapy in combination with 1) a CDK4/6 inhibitor, with or without HER2-directed therapy, or 2) a CDK 4/6 inhibitor in combination with a PI3K/AKT inhibitor, in the metastatic or locally advanced. 11. Presence of a severe medical condition or psychiatric condition or medications that would preclude participation of the study intervention.
Conditions Autism Spectrum Disorder, Depression, An...
Phase NA
Enrollment 300
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Autistic adults are at a greater risk for mental health problems compared to the general population, with 50% meeting criteria for a co-occurring psychiatric condition. Depression and anxiety are the most common of these conditions among autistic adults, contributing to long-term detrimental effects on health, day-to-day functioning, and quality of life. This study will conduct the first large-scale head-to-head comparison of the two most widely studied mental health interventions for autistic adults: cognitive-behavioral therapy (CBT) and mindfulness-based therapy (MBT). Both interventions are well-established, empirically supported treatments for depression and anxiety in the general population, and both interventions have demonstrated efficacy among autistic adults. However, their comparative effectiveness and heterogeneity of treatment effects have not been established in autistic adults. Both interventions will be delivered by telehealth.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Cognitive-Behavioral Therapy (CBT) — The UP incorporates common principles among empirically supported CBT protocols, including restructuring maladaptive cognitions, changing maladaptive behaviors, preventing emotion avoidance, and incorporating exposure. It consists of five core treatment modules: 1. emotion awareness, 2. cognitive appraisal \& reappraisal, 3. emotion avoidance \& emotion-driven behaviors, 4. awareness and tolerance of emotion-related physical sensations, \& 5. interoceptive and situational emotion-focused exposures. There are two introductory modules on enhancing motivation and understanding of emotional experiences. A final module is on maintenance and relapse prevention. Modules are delivered at a flexible pace and some patients may spend multiple sessions on the same module. The total number of sessions varies from patient to patient, generally ranging from 12-18 sessions (50-60 minutes) delivered weekly. All sessions are 1:1 via telehealth.
  • Behavioral: Mindfulness-Based Cognitive Therapy (MBCT) — The study MBCT protocol is a 9-week program (90-120 minute sessions) with home-based practice between sessions. MBCT sessions incorporate formal mindfulness meditation practices such as sitting meditation, mindful movement, and body scan (with a focus on mindful and non-judgmental attention to sensations, thoughts, and feelings), as well as informal practices and homework to integrate mindful awareness into everyday life, such as mindful eating, mindful walking, and mindful breathing. All sessions are 1:1 via telehealth.

Primary Outcomes

  • Change in anxiety and depression symptoms (Baseline, up to 18 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-17
Completion: 2027-02-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of North Carolina, Chapel Hill
Collaborators: University of Virginia, Augusta University, Patient-Centered Outcomes Research Institute
Principal Investigators:
  • Laura Klinger, PhD (PRINCIPAL_INVESTIGATOR) - University of North Carolina, Chapel Hill
  • Micah Mazurek, PhD (PRINCIPAL_INVESTIGATOR) - University of Virginia
Contact Information
Study Contact:
Laura Klinger, PhD
(919) 966-8183
laura_klinger@med.unc.edu
Laura Klinger, PhD
919-966-8183
laura_klinger@med.unc.edu
University of North Carolina at Chapel Hill
Micah Mazurek, PhD
434-924-5692
mm5gt@virginia.edu
University of Virginia
Interventions
  • Behavioral: Cognitive-Behavioral Therapy (CBT) — The UP incorporates common principles among empirically supported CBT protocols, including restructuring maladaptive cognitions, changing maladaptive behaviors, preventing emotion avoidance, and incorporating exposure. It consists of five core treatment modules: 1. emotion awareness, 2. cognitive appraisal \& reappraisal, 3. emotion avoidance \& emotion-driven behaviors, 4. awareness and tolerance of emotion-related physical sensations, \& 5. interoceptive and situational emotion-focused exposures. There are two introductory modules on enhancing motivation and understanding of emotional experiences. A final module is on maintenance and relapse prevention. Modules are delivered at a flexible pace and some patients may spend multiple sessions on the same module. The total number of sessions varies from patient to patient, generally ranging from 12-18 sessions (50-60 minutes) delivered weekly. All sessions are 1:1 via telehealth.
  • Behavioral: Mindfulness-Based Cognitive Therapy (MBCT) — The study MBCT protocol is a 9-week program (90-120 minute sessions) with home-based practice between sessions. MBCT sessions incorporate formal mindfulness meditation practices such as sitting meditation, mindful movement, and body scan (with a focus on mindful and non-judgmental attention to sensations, thoughts, and feelings), as well as informal practices and homework to integrate mindful awareness into everyday life, such as mindful eating, mindful walking, and mindful breathing. All sessions are 1:1 via telehealth.
Study Locations (2 sites)
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27510 United States
University of Virginia, Charlottesville, Virginia 22903 United States
Eligibility Criteria
Inclusion Criteria: * ≥18 years of age * Co-occurring depression and/or anxiety as determined by a total score ≥10 on the PHQ-ADS * Living in North Carolina or Virginia * Ability to participate in therapy sessions over telehealth * English-speaking * Provide proof of a professional diagnosis of autism OR meet or exceed clinical cut-off on the Social Responsiveness Scale (SRS-2) autism screening instrument Exclusion Criteria: * Altered mental status that precludes the ability to provide informed assent or consent (acute psychosis, intoxication, or mania) * Imminent risk of suicide
Conditions Breast Cancer
Phase Not Applicable
Enrollment 1098
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The advances in early detection coupled with improvements in treatments have led to an ever increasing number of breast cancer survivors. New methods to improve outcomes, including strategies aimed at improving the quality of life and reducing the risk of other diseases, may complement the currently available treatment options. In particular, interventions targeting diet, weight and physical activity can reduce the risk of cancer occurrence, prevent cancer recurrence, and improve survival and the quality of life.This cross-sectional, prospective, observational study aims at evaluating dietary habits and nutritional knowledge in patients with early hormone receptor positive and hormone receptor negative breast cancer.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Evaluation of nutritional knowledge in patients with surgically removed early breast cancer (At baseline and at 3-5 years of follow up)
  • Evaluation of dietary habits in patients with surgically removed early breast cancer (At baseline and at 3-5 years of follow up)
  • Evaluation of physical activity in patients with surgically removed early breast cancer (At baseline and at 3-5 years of follow up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-10-28
Completion: 2032-07-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 1098 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centro di Riferimento Oncologico - Aviano
Principal Investigators:
  • Mattia Garutti, MD (PRINCIPAL_INVESTIGATOR) - IRCCS-Centro di Riferimento Oncologico (CRO), Aviano (PN)
Contact Information
Study Contact:
Mattia Garutti, MD
0434 659092
mattia.garutti@cro.it
Giulia Cudia, MSc
giulia.cudia@cro.it
Mattia Garutti, MD
0434 659092
mattia.garutti@cro.it
IRCCS, Centro di Riferimento Oncologico (CRO) di Aviano
Interventions
N/A
Study Locations (1 sites)
IRCCS, Centro di Riferimento Oncologico (CRO) di Aviano, Aviano, Pordonone 33081 Italy
Eligibility Criteria
Inclusion Criteria: * Patients with surgically removed early stage (I-IIIa) hormone receptor-positive or hormone receptor negative breast cancer. Patients with hormone receptor-positive breast cancer can be in treatment with endocrine therapy; patients with hormone receptor-negative tumors have to be in follow-up. Concomitant use of targeted therapies with anti-hormonal agents is allowed only in adjuvant setting * Female patients ≥18 years of age. * Written informed consent must be obtained before any study-related assessment is performed Exclusion Criteria: * Patients with advanced/metastatic breast cancer. * Patients with early breast cancer receiving (neo)adjuvant chemotherapy or anti-HER2 agents * Patients receiving active treatment for secondary primary tumors (excluding basal cell carcinoma or in situ neoplasias)
Conditions Cancer of Breast, Depressive Symptoms, C...
Phase NA
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is funded by the HEAL Initiative (https://heal.nih.gov/). Based on Preliminary Studies (PSs), the research team developed and pilot-tested an evidence-based Web App-based information and coaching/support program for cancer pain management (CAPA) that was culturally tailored to Asian American breast cancer survivors using multiple unique features. However, CAPA rarely considered depressive symptoms accompanying pain in its design or components, and PSs indicated the necessity of further individualization of the intervention components of CAPA due to diversities in the needs of ABD. The purpose of the proposed 2-phase study is to further develop CAPA with additional components for ABD and the individual optimization functionality (CAI) and to test the efficacy of CAI in improving cancer pain experience of ABD. The specific aims are to: a) develop and evaluate CAI through an expert review and a usability test (R61 phase); b) determine whether the intervention group (that uses CAI and usual care) will show significantly greater improvements than the active control group (that uses CAPA and usual care) in primary outcomes (cancer pain management and cancer pain experience including depressive symptoms) from baseline to post 1-month and post 3-months; c) identify theory-based variables (attitudes, self-efficacy, perceived barriers, and social influences) that mediate the intervention effects of CAI on the primary outcomes; and d) determine whether the effects of CAI on the primary outcomes are moderated by selected background, disease, genetic, and situational factors. This study is guided by the Bandura's Theory and the stress and coping framework by Lazarus and Folkman. The R61 phase includes: (a) the intervention development process, (b) a usability test among 15 ABD, 15 family members, and 15 community gatekeepers; and (c) an expert review among 10 experts in oncology. The R33 phase adopts a randomized repeated measures control group design among 300 ABD. Long-term goals are: (a) to extend and test CAI in various healthcare settings with diverse subgroups of ABD, (b) examine the costeffectiveness, sustainability, and scalability of CAI in the settings, and (c) translate CAI into health care for ABD.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: CAI — Web App-based information and coaching/support program for cancer pain management with additional components for the individual optimization functionality
  • Behavioral: CAPA — Web App-based information and coaching/support program for cancer pain management

Primary Outcomes

  • Cancer Pain Management (CPM) (Pretest, Post 1-month, Post 3-months)
  • Brief Pain Inventory-Short Form (BPI-SF) (Pretest, Post 1-month, Post 3-months)
  • Activity monitoring device (Fitbit) as a tool for digital pain biomarkers (Pretest, Post 1-month, Post 3-months)
  • Memorial Symptom Assessment Scale-Short Form (MSAS-SF) (Pretest, Post 1-month, Post 3-months)
  • Center for Epidemiologic Studies Depression Scale (CES-D) (Pretest, Post 1-month, Post 3-months)
  • Functional Assessment of Cancer Therapy Scale-Breast Cancer (FACT-B) (Pretest, Post 1-month, Post 3-months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-20
Completion: 2027-08-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Texas at Austin
Principal Investigators:
  • Eun Ok Im (PRINCIPAL_INVESTIGATOR) - The University of Texas at Austin
Contact Information
Study Contact:
Wonshik Chee
512-232-2142
cai.help@austin.utexas.edu
OVPR
512-471-2877
research@utexas.edu
Wonshik Chee
512-232-2142
cai.help@austin.utexas.edu
The University of Texas at Austin
Interventions
  • Behavioral: CAI — Web App-based information and coaching/support program for cancer pain management with additional components for the individual optimization functionality
  • Behavioral: CAPA — Web App-based information and coaching/support program for cancer pain management
Study Locations (1 sites)
The University of Texas at Austin, Austin, Texas 78712 United States
Eligibility Criteria
Inclusion Criteria: * women aged 18 years and older who identify as Chinese, Korean, or Japanese; * have had a breast cancer diagnosis in the past; * can read and write English, Mandarin (simplified or traditional), Korean, or Japanese; * have access to the internet through computers or mobile devices (mobile phones and tablets); * have experienced cancer pain during the past week (at least 1 on a scale from 0 to 5 \[no symptom=0, mild symptom that does not bother=1, somewhat bothering symptom=2, moderate symptom=3, severe symptom=4, and worst possible symptom=5\]); * have experienced depressive symptoms during the past two weeks (1 to 10 on the Patient Health Questionnaire) which is equivalent to the cut-point of minimal to moderate depression. Exclusion Criteria: * less than 18 years old because their cancer experience would be different from that of adults. * Those who are in treatment or not in treatment, but who were diagnosed with breast cancer within the past five years, will be excluded. * Those who participated in the PI's pilot studies will be excluded. * The participants of R33 phase will exclude those in active depression treatment regardless of their level of depression. * Those without Internet access will be excluded, but those with Internet access through community/group computers will be included.